Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 8529 | 0.67 |
09:56 ET | 202 | 0.7 |
09:59 ET | 1500 | 0.6702 |
10:14 ET | 300 | 0.7067 |
10:19 ET | 500 | 0.6868 |
10:30 ET | 100 | 0.6702 |
10:32 ET | 4608 | 0.67 |
10:33 ET | 100 | 0.6776 |
10:37 ET | 1525 | 0.68 |
10:39 ET | 5200 | 0.6925 |
10:42 ET | 2400 | 0.6767 |
10:48 ET | 900 | 0.687 |
11:02 ET | 100 | 0.6867 |
11:08 ET | 6944 | 0.69 |
11:09 ET | 801 | 0.69 |
11:11 ET | 580 | 0.69 |
11:18 ET | 100 | 0.69 |
11:31 ET | 4600 | 0.6901 |
11:33 ET | 6726 | 0.6901 |
11:38 ET | 100 | 0.69 |
11:44 ET | 110 | 0.6901 |
11:51 ET | 1000 | 0.69 |
12:00 ET | 125 | 0.6958 |
12:02 ET | 3000 | 0.6898 |
12:09 ET | 20639 | 0.675 |
12:12 ET | 100 | 0.6799 |
12:16 ET | 2851 | 0.6715 |
12:18 ET | 1200 | 0.6715 |
12:21 ET | 596 | 0.6715 |
12:52 ET | 1000 | 0.6797 |
12:54 ET | 500 | 0.6797 |
12:59 ET | 600 | 0.6796 |
01:08 ET | 6700 | 0.6798 |
01:17 ET | 3005 | 0.6702 |
01:19 ET | 200 | 0.6702 |
01:28 ET | 198 | 0.6798 |
01:30 ET | 1000 | 0.675 |
01:44 ET | 100 | 0.671 |
01:55 ET | 200 | 0.6798 |
01:57 ET | 100 | 0.671 |
02:11 ET | 200 | 0.671 |
02:26 ET | 200 | 0.6798 |
02:31 ET | 100 | 0.6798 |
02:33 ET | 2481 | 0.6702 |
02:44 ET | 672 | 0.6703 |
02:47 ET | 142 | 0.6798 |
02:49 ET | 100 | 0.6702 |
02:51 ET | 138 | 0.679 |
02:56 ET | 100 | 0.6798 |
02:58 ET | 100 | 0.6702 |
03:02 ET | 380 | 0.6653 |
03:05 ET | 600 | 0.6653 |
03:20 ET | 500 | 0.671 |
03:30 ET | 11699 | 0.6652 |
03:36 ET | 400 | 0.6686 |
03:45 ET | 100 | 0.668 |
03:56 ET | 230 | 0.679799 |
03:59 ET | 100 | 0.6799 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 24.0M | -2.0x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.2M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.6M | 0.5x | +78.05% |
CASI Pharmaceuticals Inc | 76.8M | -2.5x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.0M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.81 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.